Summit Therapeutics Expands Its Clinical Development Program For Ivonescimab Into Urothelial Carcinoma An Orbladder Cancer, With The Initiation Of The Global, Multi-Regional Phase II/III HARMONi-GU1 Trial

Summit Therapeutics Inc

Summit Therapeutics Inc

SMMT

0.00

HARMONi-GU1 Is First Global Registrational Clinical Trial of Ivonescimab in a Genitourinary (GU) Cancer, Adding to Global Phase III Ivonescimab Studies in NSCLC and CRC

Clinical Trial Site Activations Globally Planned to Begin by Q4 2026

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.